Muscular Dystrophy Trial, Recruiting NCT06075693 Sponsor: Massachusetts General Hospital Condition: Muscular Dystrophy
Back to Muscular Dystrophy

Muscular Dystrophy Trial, Recruiting

NCT06075693
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with a condition called Myotonic Dystrophy Type 1 (DM1), either through genetic testing and/or based on symptoms — even if you have no symptoms yet, or if you chose not to have genetic testing done.
  • You are an "unaffected" participant, meaning you are not known to have myotonic dystrophy or any other muscular dystrophy, and you may not have had genetic testing.
  • You are able to give your own consent to take part in the study.
  • You are male or female and are 18 years of age or older.

Who may not be able to join:

  • You have a history of a weakened immune system, pre-existing liver or kidney disease, HIV, or hepatitis B and/or C.
  • You have taken blood-thinning (anticoagulant) medications within the past 60 days before a spinal fluid collection procedure, or anti-platelet drugs (such as aspirin or similar medicines) within the past 7 days before a blood draw.
  • You have any metal inside your body, such as a pacemaker, defibrillator, certain heart valves or stents, an artificial joint, an aneurysm clip, or an inner ear device; or you have a history of working with sheet metal or have metal shrapnel in your body — all of which would make an MRI scan unsafe.
  • You are pregnant, as MRI scans may affect an unborn baby.
  • There are signs of increased pressure in the brain or an active infection, or your platelet count (a measure of blood clotting cells) is below 50,000 — which would make a spinal fluid collection procedure unsafe (confirm with trial site).
  • You are unwilling or unable to provide written consent to participate.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Thurman M Wheeler, MD, Massachusetts General Hospital

Phone: 617-726-7506

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 August 2022
Est. completion
1 August 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Extracellular RNA splice variants in biofluids

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov